I coined the term “Typo-gate” to describe the misguided dustup Alnylam Pharmaceuticals executives instigated last Friday when they asserted cardiologist Sarah Cuddy made mistakes during her discussant’s talk following the presentation of the vutrisiran HELIOS-B study results.
The final verdict is the opposite. Alnylam was wrong, Cuddy was right.
A cardiologist at Brigham and Women’s Hospital, Cuddy performed her own analysis comparing all-cause mortality for vutrisiran and BridgeBio’s competing drug acoramidis, based on data from their respective placebo-controlled Phase 3 studies in ATTR-CM, an increasingly diagnosed heart disease.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
